HER-2 positive
HER-2 positive
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Salivary Gland Cancer
Salivary Gland Cancer
|
cisplatin + doxorubicin hydrochloride + cyclophosphamide oral
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Salivary Gland Cancer
Salivary Gland Cancer
|
cisplatin + vinorelbine tartrate
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Salivary Gland Cancer
Salivary Gland Cancer
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Salivary Gland Cancer
Salivary Gland Cancer
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Salivary Gland Cancer
Salivary Gland Cancer
|
larotrectinib
Sensitive: A2 - Guideline
|
NTRK3 fusion
NTRK3 fusion
|
Salivary Gland Cancer
Salivary Gland Cancer
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK1 fusion
NTRK1 fusion
|
Salivary Gland Cancer
Salivary Gland Cancer
|
entrectinib
Sensitive: A2 - Guideline
|
NTRK2 fusion
NTRK2 fusion
|
Salivary Gland Cancer
Salivary Gland Cancer
|
entrectinib
Sensitive: A2 - Guideline
|
|
Salivary Gland Cancer
Salivary Gland Cancer
|
leuprolide acetate
Sensitive: A2 - Guideline
|
|
Salivary Gland Cancer
Salivary Gland Cancer
|
bicalutamide
Sensitive: A2 - Guideline
|
PD-L1 expression
PD-L1 expression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
pembrolizumab
Sensitive: C1 - Off-label
|
HER-2 overexpression
HER-2 overexpression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab
Sensitive: C1 - Off-label
|
|
Salivary Gland Cancer
Salivary Gland Cancer
|
selpercatinib
Sensitive: C1 - Off-label
|
|
Salivary Gland Cancer
Salivary Gland Cancer
|
pralsetinib
Sensitive: C1 - Off-label
|
HER-2 overexpression
HER-2 overexpression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab
Sensitive: C2 – Inclusion Criteria
|
HER-2 amplification
HER-2 amplification
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab
Sensitive: C2 – Inclusion Criteria
|
|
Salivary Gland Cancer
Salivary Gland Cancer
|
leuprolide acetate + bicalutamide
Sensitive: C3 – Early Trials
|
PLIN2 expression
PLIN2 expression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
leuprolide acetate + bicalutamide
Sensitive: C3 – Early Trials
|
|
Salivary Gland Cancer
Salivary Gland Cancer
|
AZD5363
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
ARX788
Sensitive: C3 – Early Trials
|
HRAS mutation
HRAS mutation
|
Salivary Gland Cancer
Salivary Gland Cancer
|
tipifarnib
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Salivary Gland Cancer
Salivary Gland Cancer
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
|
HER-2 expression
HER-2 expression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
|
PTEN expression
PTEN expression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
bicalutamide
Sensitive: C3 – Early Trials
|
PTEN expression
PTEN expression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab
Sensitive: C3 – Early Trials
|
PTCH1 mutation
PTCH1 mutation
|
Salivary Gland Cancer
Salivary Gland Cancer
|
vismodegib
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Salivary Gland Cancer
Salivary Gland Cancer
|
pyrotinib
Sensitive: C3 – Early Trials
|
HER-2 amplification
HER-2 amplification
|
Salivary Gland Cancer
Salivary Gland Cancer
|
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
|
HER-2 overexpression
HER-2 overexpression
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
|
|
Salivary Gland Cancer
Salivary Gland Cancer
|
crizotinib + pazopanib
Sensitive: C3 – Early Trials
|
AR positive + HER-2 amplification
AR positive + HER-2 amplification
|
Salivary Gland Cancer
Salivary Gland Cancer
|
leuprolide acetate + bicalutamide
Sensitive: C4 – Case Studies
|
BAG4-FGFR1 B2F6
BAG4-FGFR1 B2F6
|
Salivary Gland Cancer
Salivary Gland Cancer
|
ABSK-091
Sensitive: C4 – Case Studies
|
ETV6-NTRK3 fusion
ETV6-NTRK3 fusion
|
Salivary Gland Cancer
Salivary Gland Cancer
|
entrectinib
Resistant: C4 – Case Studies
|
PIK3CA H1047R
PIK3CA H1047R
|
Salivary Gland Cancer
Salivary Gland Cancer
|
vandetanib
Sensitive: C4 – Case Studies
|
HER-2 amplification + HER-2 mutation
HER-2 amplification + HER-2 mutation
|
Salivary Gland Cancer
Salivary Gland Cancer
|
trastuzumab
Sensitive: C4 – Case Studies
|
